噻唑烷二酮
过氧化物酶体增殖物激活受体
罗格列酮
曲格列酮
吡格列酮
核受体
葡萄糖稳态
脂肪生成
转录因子
视黄醇X受体
受体
血管生成
癌症研究
生物
化学
医学
内科学
内分泌学
生物化学
2型糖尿病
脂肪组织
糖尿病
胰岛素抵抗
基因
作者
Suvadeep Mal,Ashish Ranjan Dwivedi,Vijay Kumar,Naveen Kumar,Bhupinder Kumar,Vinod Kumar
标识
DOI:10.2174/0929867327666200716113136
摘要
Peroxisome proliferator-activated receptor (PPAR), a ligand dependant transcription factor, is a member of the nuclear receptor superfamily. PPAR exists in three isoforms i.e. PPAR alpha (PPARα), PPAR beta (PPARβ), and PPAR gamma (PPARγ). These are multi-functional transcription factors and help in regulating inflammation, type 2 diabetes, lipid concentration in the body, metastasis, and tumor growth or angiogenesis. Activation of PPARγ causes inhibition of growth of cultured human breast, gastric, lung, prostate, and other cancer cells. PPARγ is mainly involved in fatty acid storage, glucose metabolism, and homeostasis and adipogenesis regulation. A large number of natural and synthetic ligands bind to PPARγ and modulate its activity. Ligands such as thiazolidinedione, troglitazone, rosiglitazone, pioglitazone effectively bind to PPARγ; however, most of these were found to display severe side effects such as hepatotoxicity, weight gain, cardiovascular complications and bladder tumor. Now the focus is shifted towards the development of dual-acting or pan PPAR ligands. The current review article describes the functions and role of PPARγ in various disease states. In addition, recently reported PPARγ ligands and pan PPAR ligands were discussed in detail. It is envisaged that the present review article may help in the development of potent PPAR ligands with no or minimal side effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI